Charles Baum, Md, Phd Email and Phone Number

Dr. Baum served as President, Chief Executive Officer, Founder and Board Member of Mirati Therapeutics from 2012 to 2024 when Mirati was acquired by BMS. Under his leadership, Mirati became a leading research and development precision oncology company focused on the discovery, development and commercialization of novel therapies that target the genetic drivers of cancer. Adagrasib (Krazati), a potent and selective KRAS G12C inhibitor was approved for second line NSCLC patients in December of 2022. Clinical stage programs include MRTX 1719, an MTA cooperative PRMT5 inhibitor, MRTX 0902 a SOS-1 inhibitor being developed in combination with adagrasib and MRTX 1133 a potent and selective KRAS G12D inhibitor. Mirati is also advancing its differentiated preclinical portfolio including next generation KRAS inhibitors. Prior to joining Mirati, Chuck was Senior Vice President for Biotherapeutic Clinical Research within Pfizer’s Worldwide Research & Development division. He was at Pfizer from 2003 to 2012, serving in roles of increasing responsibility and was responsible for the clinical development of several oncology programs including Inlyta, Xalkori, Ibrance and the approval of Sutent. Prior to Pfizer, Chuck was at Schering-Plough where he was responsible for the Phase I-IV development of several oncology compounds, including Temodar.Chuck’s career has also included academic and hospital positions at Stanford and Emory universities. He currently serves on the board of PMV Pharmaceuticals, Inc., Poseida Therapeutics, Acrivon, Odyssey, and Terremoto Biosciences. He served as a member of the board of Array Biopharma from 2014 to 2019 when it was acquired by Pfizer, Inc. and Immunomedics from 2019 to 2020 when it was acquired by Gilead.Chuck received his M.D. and Ph.D. degrees from Washington University School of Medicine and completed his post-graduate training at Stanford University.

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.

Leader of sunitinib program 2003-2006, Head of Oncology Development 2006 to 2009 with responsibility for axitinib, crizotinib and all oncology programs. Cheif Medical officier and Senior Vice President of Clinical Research for biotherapeutics division 2009-2010. SVP and Head of Clinical Research responsible for all aspects of clinical development for biotherapeutic programs in oncology, biosimilars, metabolism, cardiovascular and therapeutic vaccines (2010-2012).

Led several oncology programs including temozolomide, sarasar, p53 gene therapy and others.

Led biologic oncology programs.